nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisinopril—ACE—systemic scleroderma	0.314	1	CbGaD
Lisinopril—Enalapril—Captopril—systemic scleroderma	0.29	1	CrCrCtD
Lisinopril—ACE—Captopril—systemic scleroderma	0.153	0.599	CbGbCtD
Lisinopril—SLC15A1—Captopril—systemic scleroderma	0.0614	0.24	CbGbCtD
Lisinopril—ABCB1—Captopril—systemic scleroderma	0.0151	0.0589	CbGbCtD
Lisinopril—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0119	0.0464	CbGbCtD
Lisinopril—ABCB1—Prednisone—systemic scleroderma	0.00949	0.0371	CbGbCtD
Lisinopril—ACE—forelimb zeugopod—systemic scleroderma	0.00638	0.214	CbGeAlD
Lisinopril—ACE—pulmonary artery—systemic scleroderma	0.00477	0.16	CbGeAlD
Lisinopril—ABCB1—Methotrexate—systemic scleroderma	0.00476	0.0186	CbGbCtD
Lisinopril—ACE—skeletal joint—systemic scleroderma	0.00422	0.142	CbGeAlD
Lisinopril—ACE—umbilical vein—systemic scleroderma	0.00315	0.106	CbGeAlD
Lisinopril—ACE2—Metabolism of Angiotensinogen to Angiotensins—ACE—systemic scleroderma	0.0023	0.275	CbGpPWpGaD
Lisinopril—ACE2—ACE Inhibitor Pathway—ACE—systemic scleroderma	0.00219	0.262	CbGpPWpGaD
Lisinopril—ACE—artery—systemic scleroderma	0.00177	0.0593	CbGeAlD
Lisinopril—ACE2—digestive system—systemic scleroderma	0.00156	0.0523	CbGeAlD
Lisinopril—ACE—endothelium—systemic scleroderma	0.00149	0.0501	CbGeAlD
Lisinopril—ACE—blood vessel—systemic scleroderma	0.00138	0.0462	CbGeAlD
Lisinopril—ACE2—lung—systemic scleroderma	0.0013	0.0437	CbGeAlD
Lisinopril—ACE2—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.00102	0.122	CbGpPWpGaD
Lisinopril—SLC15A1—digestive system—systemic scleroderma	0.000712	0.0238	CbGeAlD
Lisinopril—ACE—connective tissue—systemic scleroderma	0.000706	0.0237	CbGeAlD
Lisinopril—ACE2—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.000675	0.0807	CbGpPWpGaD
Lisinopril—ACE—smooth muscle tissue—systemic scleroderma	0.000646	0.0217	CbGeAlD
Lisinopril—ACE2—Peptide hormone metabolism—ACE—systemic scleroderma	0.000605	0.0723	CbGpPWpGaD
Lisinopril—ACE—digestive system—systemic scleroderma	0.00051	0.0171	CbGeAlD
Lisinopril—ABCB1—blood vessel—systemic scleroderma	0.000485	0.0163	CbGeAlD
Lisinopril—Fosinopril—ACE—systemic scleroderma	0.000476	0.152	CrCbGaD
Lisinopril—ACE—ACE Inhibitor Pathway—NOS3—systemic scleroderma	0.000456	0.0545	CbGpPWpGaD
Lisinopril—ACE—lung—systemic scleroderma	0.000426	0.0143	CbGeAlD
Lisinopril—Spirapril—ACE—systemic scleroderma	0.000383	0.123	CrCbGaD
Lisinopril—Moexipril—ACE—systemic scleroderma	0.000367	0.118	CrCbGaD
Lisinopril—Quinapril—ACE—systemic scleroderma	0.000342	0.11	CrCbGaD
Lisinopril—Cilazapril—ACE—systemic scleroderma	0.000342	0.11	CrCbGaD
Lisinopril—Ramipril—ACE—systemic scleroderma	0.000331	0.106	CrCbGaD
Lisinopril—Trandolapril—ACE—systemic scleroderma	0.000331	0.106	CrCbGaD
Lisinopril—ACE—ACE Inhibitor Pathway—TGFB1—systemic scleroderma	0.000302	0.036	CbGpPWpGaD
Lisinopril—Benazepril—ACE—systemic scleroderma	0.000297	0.0953	CrCbGaD
Lisinopril—Enalapril—ACE—systemic scleroderma	0.000251	0.0804	CrCbGaD
Lisinopril—ABCB1—digestive system—systemic scleroderma	0.00018	0.00602	CbGeAlD
Lisinopril—ABCB1—lung—systemic scleroderma	0.00015	0.00503	CbGeAlD
Lisinopril—ACE2—Metabolism of proteins—ACE—systemic scleroderma	0.000114	0.0137	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—MMP1—systemic scleroderma	7.34e-05	0.00877	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—IL13—systemic scleroderma	6.78e-05	0.0081	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	6.01e-05	0.00718	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—CCL2—systemic scleroderma	5.97e-05	0.00713	CbGpPWpGaD
Lisinopril—Constipation—Leflunomide—systemic scleroderma	5.92e-05	0.000603	CcSEcCtD
Lisinopril—Anaemia—Mycophenolate mofetil—systemic scleroderma	5.9e-05	0.000601	CcSEcCtD
Lisinopril—Dyspnoea—Mycophenolic acid—systemic scleroderma	5.88e-05	0.0006	CcSEcCtD
Lisinopril—Somnolence—Mycophenolic acid—systemic scleroderma	5.87e-05	0.000598	CcSEcCtD
Lisinopril—Angioedema—Mycophenolate mofetil—systemic scleroderma	5.83e-05	0.000594	CcSEcCtD
Lisinopril—Dyspepsia—Mycophenolic acid—systemic scleroderma	5.81e-05	0.000592	CcSEcCtD
Lisinopril—Neutropenia—Prednisone—systemic scleroderma	5.81e-05	0.000592	CcSEcCtD
Lisinopril—Abdominal pain—Azathioprine—systemic scleroderma	5.79e-05	0.00059	CcSEcCtD
Lisinopril—Body temperature increased—Azathioprine—systemic scleroderma	5.79e-05	0.00059	CcSEcCtD
Lisinopril—Malaise—Mycophenolate mofetil—systemic scleroderma	5.76e-05	0.000586	CcSEcCtD
Lisinopril—Diarrhoea—Captopril—systemic scleroderma	5.74e-05	0.000585	CcSEcCtD
Lisinopril—Decreased appetite—Mycophenolic acid—systemic scleroderma	5.74e-05	0.000585	CcSEcCtD
Lisinopril—Vertigo—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000584	CcSEcCtD
Lisinopril—Irritability—Methotrexate—systemic scleroderma	5.73e-05	0.000584	CcSEcCtD
Lisinopril—Syncope—Mycophenolate mofetil—systemic scleroderma	5.72e-05	0.000583	CcSEcCtD
Lisinopril—Erectile dysfunction—Prednisone—systemic scleroderma	5.72e-05	0.000583	CcSEcCtD
Lisinopril—Leukopenia—Mycophenolate mofetil—systemic scleroderma	5.71e-05	0.000582	CcSEcCtD
Lisinopril—Feeling abnormal—Leflunomide—systemic scleroderma	5.7e-05	0.000581	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	5.7e-05	0.000581	CcSEcCtD
Lisinopril—Fatigue—Mycophenolic acid—systemic scleroderma	5.69e-05	0.00058	CcSEcCtD
Lisinopril—ACE2—Metabolism of proteins—MMP2—systemic scleroderma	5.68e-05	0.00678	CbGpPWpGaD
Lisinopril—Nausea—Mometasone—systemic scleroderma	5.68e-05	0.000578	CcSEcCtD
Lisinopril—Gastrointestinal pain—Leflunomide—systemic scleroderma	5.66e-05	0.000576	CcSEcCtD
Lisinopril—Weight increased—Prednisone—systemic scleroderma	5.65e-05	0.000576	CcSEcCtD
Lisinopril—Ataxia—Methotrexate—systemic scleroderma	5.65e-05	0.000575	CcSEcCtD
Lisinopril—Constipation—Mycophenolic acid—systemic scleroderma	5.64e-05	0.000575	CcSEcCtD
Lisinopril—Pain—Mycophenolic acid—systemic scleroderma	5.64e-05	0.000575	CcSEcCtD
Lisinopril—Palpitations—Mycophenolate mofetil—systemic scleroderma	5.64e-05	0.000575	CcSEcCtD
Lisinopril—Weight decreased—Prednisone—systemic scleroderma	5.62e-05	0.000572	CcSEcCtD
Lisinopril—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	5.61e-05	0.000572	CcSEcCtD
Lisinopril—Hyperglycaemia—Prednisone—systemic scleroderma	5.6e-05	0.000571	CcSEcCtD
Lisinopril—Cough—Mycophenolate mofetil—systemic scleroderma	5.57e-05	0.000567	CcSEcCtD
Lisinopril—Dizziness—Captopril—systemic scleroderma	5.55e-05	0.000566	CcSEcCtD
Lisinopril—Depression—Prednisone—systemic scleroderma	5.52e-05	0.000562	CcSEcCtD
Lisinopril—Urticaria—Leflunomide—systemic scleroderma	5.5e-05	0.00056	CcSEcCtD
Lisinopril—Body temperature increased—Leflunomide—systemic scleroderma	5.47e-05	0.000557	CcSEcCtD
Lisinopril—Abdominal pain—Leflunomide—systemic scleroderma	5.47e-05	0.000557	CcSEcCtD
Lisinopril—Acute coronary syndrome—Prednisone—systemic scleroderma	5.46e-05	0.000556	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	5.45e-05	0.00651	CbGpPWpGaD
Lisinopril—Feeling abnormal—Mycophenolic acid—systemic scleroderma	5.44e-05	0.000554	CcSEcCtD
Lisinopril—Myalgia—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000554	CcSEcCtD
Lisinopril—Chest pain—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000554	CcSEcCtD
Lisinopril—Arthralgia—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000554	CcSEcCtD
Lisinopril—Neuropathy peripheral—Prednisone—systemic scleroderma	5.43e-05	0.000553	CcSEcCtD
Lisinopril—Myocardial infarction—Prednisone—systemic scleroderma	5.43e-05	0.000553	CcSEcCtD
Lisinopril—Breast disorder—Methotrexate—systemic scleroderma	5.43e-05	0.000553	CcSEcCtD
Lisinopril—Anxiety—Mycophenolate mofetil—systemic scleroderma	5.41e-05	0.000552	CcSEcCtD
Lisinopril—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	5.41e-05	0.000551	CcSEcCtD
Lisinopril—Hypersensitivity—Azathioprine—systemic scleroderma	5.4e-05	0.00055	CcSEcCtD
Lisinopril—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	5.4e-05	0.00055	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.4e-05	0.00055	CcSEcCtD
Lisinopril—Discomfort—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.000547	CcSEcCtD
Lisinopril—Vomiting—Captopril—systemic scleroderma	5.34e-05	0.000544	CcSEcCtD
Lisinopril—Dry mouth—Mycophenolate mofetil—systemic scleroderma	5.31e-05	0.000541	CcSEcCtD
Lisinopril—Rash—Captopril—systemic scleroderma	5.29e-05	0.000539	CcSEcCtD
Lisinopril—Dermatitis—Captopril—systemic scleroderma	5.29e-05	0.000539	CcSEcCtD
Lisinopril—Headache—Captopril—systemic scleroderma	5.26e-05	0.000536	CcSEcCtD
Lisinopril—Confusional state—Mycophenolate mofetil—systemic scleroderma	5.25e-05	0.000535	CcSEcCtD
Lisinopril—Abdominal pain—Mycophenolic acid—systemic scleroderma	5.22e-05	0.000532	CcSEcCtD
Lisinopril—Body temperature increased—Mycophenolic acid—systemic scleroderma	5.22e-05	0.000532	CcSEcCtD
Lisinopril—Oedema—Mycophenolate mofetil—systemic scleroderma	5.21e-05	0.000531	CcSEcCtD
Lisinopril—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	5.21e-05	0.000531	CcSEcCtD
Lisinopril—Asthma—Methotrexate—systemic scleroderma	5.19e-05	0.000529	CcSEcCtD
Lisinopril—Infection—Mycophenolate mofetil—systemic scleroderma	5.17e-05	0.000527	CcSEcCtD
Lisinopril—Eosinophilia—Methotrexate—systemic scleroderma	5.14e-05	0.000523	CcSEcCtD
Lisinopril—Shock—Mycophenolate mofetil—systemic scleroderma	5.12e-05	0.000522	CcSEcCtD
Lisinopril—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	5.1e-05	0.00052	CcSEcCtD
Lisinopril—Hypersensitivity—Leflunomide—systemic scleroderma	5.1e-05	0.000519	CcSEcCtD
Lisinopril—Pancreatitis—Methotrexate—systemic scleroderma	5.09e-05	0.000518	CcSEcCtD
Lisinopril—Tachycardia—Mycophenolate mofetil—systemic scleroderma	5.08e-05	0.000518	CcSEcCtD
Lisinopril—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5.06e-05	0.000515	CcSEcCtD
Lisinopril—Bradycardia—Prednisone—systemic scleroderma	5.06e-05	0.000515	CcSEcCtD
Lisinopril—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.000513	CcSEcCtD
Lisinopril—Diarrhoea—Azathioprine—systemic scleroderma	5.01e-05	0.000511	CcSEcCtD
Lisinopril—Nausea—Captopril—systemic scleroderma	4.99e-05	0.000508	CcSEcCtD
Lisinopril—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.97e-05	0.000506	CcSEcCtD
Lisinopril—Asthenia—Leflunomide—systemic scleroderma	4.96e-05	0.000506	CcSEcCtD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	4.95e-05	0.00592	CbGpPWpGaD
Lisinopril—Hallucination—Prednisone—systemic scleroderma	4.94e-05	0.000504	CcSEcCtD
Lisinopril—Pancytopenia—Methotrexate—systemic scleroderma	4.93e-05	0.000502	CcSEcCtD
Lisinopril—Pruritus—Leflunomide—systemic scleroderma	4.9e-05	0.000499	CcSEcCtD
Lisinopril—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.87e-05	0.000496	CcSEcCtD
Lisinopril—Dysuria—Methotrexate—systemic scleroderma	4.85e-05	0.000494	CcSEcCtD
Lisinopril—Neutropenia—Methotrexate—systemic scleroderma	4.85e-05	0.000494	CcSEcCtD
Lisinopril—Dizziness—Azathioprine—systemic scleroderma	4.84e-05	0.000494	CcSEcCtD
Lisinopril—Upper respiratory tract infection—Methotrexate—systemic scleroderma	4.82e-05	0.000491	CcSEcCtD
Lisinopril—Erectile dysfunction—Methotrexate—systemic scleroderma	4.78e-05	0.000487	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.75e-05	0.000484	CcSEcCtD
Lisinopril—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.74e-05	0.000483	CcSEcCtD
Lisinopril—Asthenia—Mycophenolic acid—systemic scleroderma	4.74e-05	0.000482	CcSEcCtD
Lisinopril—Diarrhoea—Leflunomide—systemic scleroderma	4.73e-05	0.000482	CcSEcCtD
Lisinopril—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.71e-05	0.00048	CcSEcCtD
Lisinopril—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.000477	CcSEcCtD
Lisinopril—Pruritus—Mycophenolic acid—systemic scleroderma	4.67e-05	0.000476	CcSEcCtD
Lisinopril—Vomiting—Azathioprine—systemic scleroderma	4.66e-05	0.000475	CcSEcCtD
Lisinopril—Pneumonia—Methotrexate—systemic scleroderma	4.65e-05	0.000474	CcSEcCtD
Lisinopril—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.64e-05	0.000473	CcSEcCtD
Lisinopril—Somnolence—Mycophenolate mofetil—systemic scleroderma	4.63e-05	0.000472	CcSEcCtD
Lisinopril—Rash—Azathioprine—systemic scleroderma	4.62e-05	0.000471	CcSEcCtD
Lisinopril—Dermatitis—Azathioprine—systemic scleroderma	4.62e-05	0.00047	CcSEcCtD
Lisinopril—Depression—Methotrexate—systemic scleroderma	4.61e-05	0.00047	CcSEcCtD
Lisinopril—Flushing—Prednisone—systemic scleroderma	4.61e-05	0.00047	CcSEcCtD
Lisinopril—Headache—Azathioprine—systemic scleroderma	4.59e-05	0.000468	CcSEcCtD
Lisinopril—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	4.59e-05	0.000467	CcSEcCtD
Lisinopril—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.59e-05	0.000467	CcSEcCtD
Lisinopril—Dizziness—Leflunomide—systemic scleroderma	4.58e-05	0.000466	CcSEcCtD
Lisinopril—Renal failure—Methotrexate—systemic scleroderma	4.55e-05	0.000463	CcSEcCtD
Lisinopril—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.53e-05	0.000461	CcSEcCtD
Lisinopril—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.52e-05	0.00046	CcSEcCtD
Lisinopril—Angiopathy—Prednisone—systemic scleroderma	4.51e-05	0.000459	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.5e-05	0.000458	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	4.49e-05	0.00536	CbGpPWpGaD
Lisinopril—Constipation—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000454	CcSEcCtD
Lisinopril—Pain—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000454	CcSEcCtD
Lisinopril—Arrhythmia—Prednisone—systemic scleroderma	4.44e-05	0.000452	CcSEcCtD
Lisinopril—Sweating—Methotrexate—systemic scleroderma	4.44e-05	0.000452	CcSEcCtD
Lisinopril—Haematuria—Methotrexate—systemic scleroderma	4.41e-05	0.000449	CcSEcCtD
Lisinopril—Vomiting—Leflunomide—systemic scleroderma	4.4e-05	0.000448	CcSEcCtD
Lisinopril—Alopecia—Prednisone—systemic scleroderma	4.39e-05	0.000447	CcSEcCtD
Lisinopril—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.38e-05	0.000446	CcSEcCtD
Lisinopril—Dizziness—Mycophenolic acid—systemic scleroderma	4.36e-05	0.000445	CcSEcCtD
Lisinopril—Epistaxis—Methotrexate—systemic scleroderma	4.36e-05	0.000445	CcSEcCtD
Lisinopril—Rash—Leflunomide—systemic scleroderma	4.36e-05	0.000444	CcSEcCtD
Lisinopril—Dermatitis—Leflunomide—systemic scleroderma	4.36e-05	0.000444	CcSEcCtD
Lisinopril—Mental disorder—Prednisone—systemic scleroderma	4.35e-05	0.000444	CcSEcCtD
Lisinopril—Nausea—Azathioprine—systemic scleroderma	4.35e-05	0.000443	CcSEcCtD
Lisinopril—Headache—Leflunomide—systemic scleroderma	4.33e-05	0.000442	CcSEcCtD
Lisinopril—Malnutrition—Prednisone—systemic scleroderma	4.33e-05	0.000441	CcSEcCtD
Lisinopril—Erythema—Prednisone—systemic scleroderma	4.33e-05	0.000441	CcSEcCtD
Lisinopril—Agranulocytosis—Methotrexate—systemic scleroderma	4.32e-05	0.00044	CcSEcCtD
Lisinopril—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	4.29e-05	0.000437	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	4.26e-05	0.00509	CbGpPWpGaD
Lisinopril—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	4.26e-05	0.000434	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	4.24e-05	0.00506	CbGpPWpGaD
Lisinopril—Vomiting—Mycophenolic acid—systemic scleroderma	4.2e-05	0.000428	CcSEcCtD
Lisinopril—Rash—Mycophenolic acid—systemic scleroderma	4.16e-05	0.000424	CcSEcCtD
Lisinopril—Dermatitis—Mycophenolic acid—systemic scleroderma	4.16e-05	0.000424	CcSEcCtD
Lisinopril—Hepatitis—Methotrexate—systemic scleroderma	4.15e-05	0.000423	CcSEcCtD
Lisinopril—Urticaria—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000422	CcSEcCtD
Lisinopril—Headache—Mycophenolic acid—systemic scleroderma	4.13e-05	0.000421	CcSEcCtD
Lisinopril—Pharyngitis—Methotrexate—systemic scleroderma	4.12e-05	0.00042	CcSEcCtD
Lisinopril—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.12e-05	0.00042	CcSEcCtD
Lisinopril—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.12e-05	0.00042	CcSEcCtD
Lisinopril—Nausea—Leflunomide—systemic scleroderma	4.11e-05	0.000419	CcSEcCtD
Lisinopril—Urinary tract disorder—Methotrexate—systemic scleroderma	4.1e-05	0.000418	CcSEcCtD
Lisinopril—Vision blurred—Prednisone—systemic scleroderma	4.08e-05	0.000415	CcSEcCtD
Lisinopril—Urethral disorder—Methotrexate—systemic scleroderma	4.07e-05	0.000415	CcSEcCtD
Lisinopril—Ill-defined disorder—Prednisone—systemic scleroderma	4.01e-05	0.000409	CcSEcCtD
Lisinopril—Anaemia—Prednisone—systemic scleroderma	4e-05	0.000407	CcSEcCtD
Lisinopril—Angioedema—Prednisone—systemic scleroderma	3.95e-05	0.000403	CcSEcCtD
Lisinopril—Erythema multiforme—Methotrexate—systemic scleroderma	3.93e-05	0.0004	CcSEcCtD
Lisinopril—Nausea—Mycophenolic acid—systemic scleroderma	3.92e-05	0.000399	CcSEcCtD
Lisinopril—Malaise—Prednisone—systemic scleroderma	3.9e-05	0.000397	CcSEcCtD
Lisinopril—Vertigo—Prednisone—systemic scleroderma	3.89e-05	0.000396	CcSEcCtD
Lisinopril—Syncope—Prednisone—systemic scleroderma	3.88e-05	0.000395	CcSEcCtD
Lisinopril—Tinnitus—Methotrexate—systemic scleroderma	3.87e-05	0.000395	CcSEcCtD
Lisinopril—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.84e-05	0.000391	CcSEcCtD
Lisinopril—Loss of consciousness—Prednisone—systemic scleroderma	3.8e-05	0.000387	CcSEcCtD
Lisinopril—Angiopathy—Methotrexate—systemic scleroderma	3.77e-05	0.000384	CcSEcCtD
Lisinopril—Mediastinal disorder—Methotrexate—systemic scleroderma	3.74e-05	0.000381	CcSEcCtD
Lisinopril—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.74e-05	0.000381	CcSEcCtD
Lisinopril—Chills—Methotrexate—systemic scleroderma	3.73e-05	0.00038	CcSEcCtD
Lisinopril—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.69e-05	0.000375	CcSEcCtD
Lisinopril—Myalgia—Prednisone—systemic scleroderma	3.68e-05	0.000375	CcSEcCtD
Lisinopril—Arthralgia—Prednisone—systemic scleroderma	3.68e-05	0.000375	CcSEcCtD
Lisinopril—Anxiety—Prednisone—systemic scleroderma	3.67e-05	0.000374	CcSEcCtD
Lisinopril—Alopecia—Methotrexate—systemic scleroderma	3.67e-05	0.000374	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.66e-05	0.000373	CcSEcCtD
Lisinopril—Discomfort—Prednisone—systemic scleroderma	3.64e-05	0.000371	CcSEcCtD
Lisinopril—Mental disorder—Methotrexate—systemic scleroderma	3.64e-05	0.000371	CcSEcCtD
Lisinopril—Erythema—Methotrexate—systemic scleroderma	3.62e-05	0.000368	CcSEcCtD
Lisinopril—Malnutrition—Methotrexate—systemic scleroderma	3.62e-05	0.000368	CcSEcCtD
Lisinopril—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.56e-05	0.000363	CcSEcCtD
Lisinopril—Dysgeusia—Methotrexate—systemic scleroderma	3.54e-05	0.000361	CcSEcCtD
Lisinopril—Anaphylactic shock—Prednisone—systemic scleroderma	3.53e-05	0.00036	CcSEcCtD
Lisinopril—Oedema—Prednisone—systemic scleroderma	3.53e-05	0.00036	CcSEcCtD
Lisinopril—Infection—Prednisone—systemic scleroderma	3.51e-05	0.000357	CcSEcCtD
Lisinopril—Back pain—Methotrexate—systemic scleroderma	3.5e-05	0.000356	CcSEcCtD
Lisinopril—Shock—Prednisone—systemic scleroderma	3.47e-05	0.000354	CcSEcCtD
Lisinopril—Tachycardia—Prednisone—systemic scleroderma	3.45e-05	0.000351	CcSEcCtD
Lisinopril—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.44e-05	0.000351	CcSEcCtD
Lisinopril—Skin disorder—Prednisone—systemic scleroderma	3.43e-05	0.000349	CcSEcCtD
Lisinopril—Hyperhidrosis—Prednisone—systemic scleroderma	3.41e-05	0.000348	CcSEcCtD
Lisinopril—Vision blurred—Methotrexate—systemic scleroderma	3.41e-05	0.000347	CcSEcCtD
Lisinopril—Anorexia—Prednisone—systemic scleroderma	3.37e-05	0.000343	CcSEcCtD
Lisinopril—Ill-defined disorder—Methotrexate—systemic scleroderma	3.35e-05	0.000342	CcSEcCtD
Lisinopril—Anaemia—Methotrexate—systemic scleroderma	3.34e-05	0.00034	CcSEcCtD
Lisinopril—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.31e-05	0.000337	CcSEcCtD
Lisinopril—Rash—Mycophenolate mofetil—systemic scleroderma	3.28e-05	0.000335	CcSEcCtD
Lisinopril—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.28e-05	0.000334	CcSEcCtD
Lisinopril—ACE—Metabolism of proteins—MMP1—systemic scleroderma	3.28e-05	0.00392	CbGpPWpGaD
Lisinopril—Headache—Mycophenolate mofetil—systemic scleroderma	3.26e-05	0.000332	CcSEcCtD
Lisinopril—Malaise—Methotrexate—systemic scleroderma	3.26e-05	0.000332	CcSEcCtD
Lisinopril—Vertigo—Methotrexate—systemic scleroderma	3.25e-05	0.000331	CcSEcCtD
Lisinopril—Leukopenia—Methotrexate—systemic scleroderma	3.24e-05	0.00033	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.22e-05	0.000328	CcSEcCtD
Lisinopril—Insomnia—Prednisone—systemic scleroderma	3.19e-05	0.000325	CcSEcCtD
Lisinopril—Paraesthesia—Prednisone—systemic scleroderma	3.17e-05	0.000323	CcSEcCtD
Lisinopril—Cough—Methotrexate—systemic scleroderma	3.16e-05	0.000321	CcSEcCtD
Lisinopril—Dyspepsia—Prednisone—systemic scleroderma	3.11e-05	0.000317	CcSEcCtD
Lisinopril—Nausea—Mycophenolate mofetil—systemic scleroderma	3.09e-05	0.000315	CcSEcCtD
Lisinopril—Myalgia—Methotrexate—systemic scleroderma	3.08e-05	0.000314	CcSEcCtD
Lisinopril—Arthralgia—Methotrexate—systemic scleroderma	3.08e-05	0.000314	CcSEcCtD
Lisinopril—Chest pain—Methotrexate—systemic scleroderma	3.08e-05	0.000314	CcSEcCtD
Lisinopril—Decreased appetite—Prednisone—systemic scleroderma	3.07e-05	0.000313	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.06e-05	0.000311	CcSEcCtD
Lisinopril—Fatigue—Prednisone—systemic scleroderma	3.04e-05	0.00031	CcSEcCtD
Lisinopril—Discomfort—Methotrexate—systemic scleroderma	3.04e-05	0.00031	CcSEcCtD
Lisinopril—Constipation—Prednisone—systemic scleroderma	3.02e-05	0.000308	CcSEcCtD
Lisinopril—Confusional state—Methotrexate—systemic scleroderma	2.98e-05	0.000303	CcSEcCtD
Lisinopril—Anaphylactic shock—Methotrexate—systemic scleroderma	2.95e-05	0.000301	CcSEcCtD
Lisinopril—Infection—Methotrexate—systemic scleroderma	2.93e-05	0.000299	CcSEcCtD
Lisinopril—Feeling abnormal—Prednisone—systemic scleroderma	2.91e-05	0.000296	CcSEcCtD
Lisinopril—Thrombocytopenia—Methotrexate—systemic scleroderma	2.89e-05	0.000294	CcSEcCtD
Lisinopril—Gastrointestinal pain—Prednisone—systemic scleroderma	2.89e-05	0.000294	CcSEcCtD
Lisinopril—Skin disorder—Methotrexate—systemic scleroderma	2.87e-05	0.000292	CcSEcCtD
Lisinopril—Hyperhidrosis—Methotrexate—systemic scleroderma	2.85e-05	0.000291	CcSEcCtD
Lisinopril—Anorexia—Methotrexate—systemic scleroderma	2.81e-05	0.000287	CcSEcCtD
Lisinopril—Urticaria—Prednisone—systemic scleroderma	2.81e-05	0.000286	CcSEcCtD
Lisinopril—Abdominal pain—Prednisone—systemic scleroderma	2.79e-05	0.000284	CcSEcCtD
Lisinopril—Body temperature increased—Prednisone—systemic scleroderma	2.79e-05	0.000284	CcSEcCtD
Lisinopril—Hypotension—Methotrexate—systemic scleroderma	2.76e-05	0.000281	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.69e-05	0.000274	CcSEcCtD
Lisinopril—Insomnia—Methotrexate—systemic scleroderma	2.67e-05	0.000272	CcSEcCtD
Lisinopril—ACE—Metabolism of proteins—CCL2—systemic scleroderma	2.67e-05	0.00318	CbGpPWpGaD
Lisinopril—Paraesthesia—Methotrexate—systemic scleroderma	2.65e-05	0.00027	CcSEcCtD
Lisinopril—Dyspnoea—Methotrexate—systemic scleroderma	2.63e-05	0.000268	CcSEcCtD
Lisinopril—Somnolence—Methotrexate—systemic scleroderma	2.62e-05	0.000267	CcSEcCtD
Lisinopril—Hypersensitivity—Prednisone—systemic scleroderma	2.6e-05	0.000265	CcSEcCtD
Lisinopril—Dyspepsia—Methotrexate—systemic scleroderma	2.6e-05	0.000265	CcSEcCtD
Lisinopril—Decreased appetite—Methotrexate—systemic scleroderma	2.57e-05	0.000261	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.55e-05	0.00026	CcSEcCtD
Lisinopril—Fatigue—Methotrexate—systemic scleroderma	2.54e-05	0.000259	CcSEcCtD
Lisinopril—ACE—Metabolism of proteins—MMP2—systemic scleroderma	2.54e-05	0.00303	CbGpPWpGaD
Lisinopril—Asthenia—Prednisone—systemic scleroderma	2.53e-05	0.000258	CcSEcCtD
Lisinopril—Pain—Methotrexate—systemic scleroderma	2.52e-05	0.000257	CcSEcCtD
Lisinopril—Pruritus—Prednisone—systemic scleroderma	2.5e-05	0.000255	CcSEcCtD
Lisinopril—Feeling abnormal—Methotrexate—systemic scleroderma	2.43e-05	0.000248	CcSEcCtD
Lisinopril—Diarrhoea—Prednisone—systemic scleroderma	2.42e-05	0.000246	CcSEcCtD
Lisinopril—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.41e-05	0.000246	CcSEcCtD
Lisinopril—Urticaria—Methotrexate—systemic scleroderma	2.34e-05	0.000239	CcSEcCtD
Lisinopril—Dizziness—Prednisone—systemic scleroderma	2.33e-05	0.000238	CcSEcCtD
Lisinopril—Body temperature increased—Methotrexate—systemic scleroderma	2.33e-05	0.000238	CcSEcCtD
Lisinopril—Abdominal pain—Methotrexate—systemic scleroderma	2.33e-05	0.000238	CcSEcCtD
Lisinopril—Vomiting—Prednisone—systemic scleroderma	2.24e-05	0.000229	CcSEcCtD
Lisinopril—Rash—Prednisone—systemic scleroderma	2.23e-05	0.000227	CcSEcCtD
Lisinopril—Dermatitis—Prednisone—systemic scleroderma	2.22e-05	0.000227	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	2.22e-05	0.00266	CbGpPWpGaD
Lisinopril—Headache—Prednisone—systemic scleroderma	2.21e-05	0.000225	CcSEcCtD
Lisinopril—Hypersensitivity—Methotrexate—systemic scleroderma	2.17e-05	0.000222	CcSEcCtD
Lisinopril—Asthenia—Methotrexate—systemic scleroderma	2.12e-05	0.000216	CcSEcCtD
Lisinopril—Nausea—Prednisone—systemic scleroderma	2.1e-05	0.000214	CcSEcCtD
Lisinopril—Pruritus—Methotrexate—systemic scleroderma	2.09e-05	0.000213	CcSEcCtD
Lisinopril—Diarrhoea—Methotrexate—systemic scleroderma	2.02e-05	0.000206	CcSEcCtD
Lisinopril—Dizziness—Methotrexate—systemic scleroderma	1.95e-05	0.000199	CcSEcCtD
Lisinopril—Vomiting—Methotrexate—systemic scleroderma	1.88e-05	0.000191	CcSEcCtD
Lisinopril—Rash—Methotrexate—systemic scleroderma	1.86e-05	0.00019	CcSEcCtD
Lisinopril—Dermatitis—Methotrexate—systemic scleroderma	1.86e-05	0.000189	CcSEcCtD
Lisinopril—Headache—Methotrexate—systemic scleroderma	1.85e-05	0.000188	CcSEcCtD
Lisinopril—Nausea—Methotrexate—systemic scleroderma	1.75e-05	0.000179	CcSEcCtD
Lisinopril—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	1.73e-05	0.00206	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	8.53e-06	0.00102	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—HSPG2—systemic scleroderma	7.27e-06	0.000868	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CTGF—systemic scleroderma	5.51e-06	0.000658	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NOS3—systemic scleroderma	2.4e-06	0.000286	CbGpPWpGaD
